Technology
Choose a subcategory:
In particular, the risks and uncertainties include, among other things: risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured; the risk that we will not achieve the anticipated benefits of
2009 Highlights Droxidopa:- Initiated Phase II trial of Droxidopa in fibromyalgia- Reported statistically significant reduction ( 87.5%) in the number of patients requiring early termination of hemodialysis sessions in Phase II trial of Dro
COMBIMATRIX CORPORATION CONSOLIDATED SUMMARY FINANCIAL INFORMATION ( In thousands, except share and per share information) ( Unaudited) CONSOLIDATED BALANCE SHEET INFORMATION: December December 31, 31, 2009 2008 Total cash, cash equivalents
Nabi Biopharmaceuticals CONSOLIDATED BALANCE SHEETS December 27, December 2008 26, ( as In thousands 2009 adjusted) ASSETS Current assets: Cash and cash equivalents $ 59,510 $ 106,438 Marketable securities 59,489 23,900 Receivables 6,690- P
CALGARY, Alberta, March 10, 2010 ( GLOBE NEWSWIRE)- Liberty Analytics Co., a leading provider of large, small- and micro-cap independent investment research, today initiated coverage on Cerus Corp..
Examples of such risks and uncertainties are: risks relating to the rigorous regulatory requirements required for approval of any drug or drug-device combination products that Discovery Labs may develop, including that: ( a) Discovery Labs
Financial Highlights CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three months ended Year ended December 31, December 30, ( In thousands of United States dollars, except per share information) 2009 2008 2009 2008 ( Unaudited) Revenues Ne
To read the entire report visit: http:// www.stockpreacher. com/n/ BIEL See what investors are saying about BIEL at penny stock forum StockPreacher. com is a small-cap research and investment commentary provider.
QLT Announces Phase II Clinical Trial Results and Development Plans for the Punctal Plug Delivery Sy
VANCOUVER, British Columbia, March 10, 2010 ( GLOBE NEWSWIRE)-- 90-Day Retention Rate of 81% for Latest Punctal Plug Prototype Device- No Dose Response Seen with Higher Doses in Phase II Clinical Studies- Expand Development Plans of the Pun
The upcoming conferences where Infinity's insights into the Hedgehog pathway and IPI-926 will be discussed include: New York Academy of Sciences " Hedgehog Pathway in Cancer" Symposium- March 17, 2010, New York City- Julian Adams, Ph. D., p
Mutual Agreement Between Japan and Singapore Regarding Tax Assessment Based on Transfer Pricing Taxa
KYOTO, Japan, March 10, 2010 ( GLOBE NEWSWIRE)- Nidec Corporation ( the " Company") today announced that it received a notice from the National Tax Agency of Japan that the relevant taxation authorities of Japan and Singapore reached a mutu
Evotec Reports Good Progress in Product Development in Treatment-Resistant Depression in its Allianc
In particular, the risks and uncertainties include, among other things: risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured; the risk that we will not achieve the anticipated benefits of